How was anastrazole discovered

Anastrozole was not discovered by accident. It was rationally designed as a third-generation aromatase inhibitor, a drug built to block the enzyme that turns androgens into estrogens [14].

The discovery came from a deliberate search for a better, safer drug than the first-generation inhibitor aminoglutethimide, which suppressed cortisol and aldosterone along with estrogen. The target was the CYP19 aromatase enzyme, a cytochrome P450 that catalyzes the three-step conversion of androstenedione to estrone [14]. Chemists at Zeneca (now AstraZeneca) synthesized a series of non-steroidal triazole compounds designed to bind the heme iron at the active site of aromatase with high selectivity, avoiding the adrenal suppression that plagued earlier drugs. Anastrozole (then called ZD1033) emerged as the lead candidate: a potent, selective inhibitor that suppressed serum estradiol by about 85% in postmenopausal women at a daily dose of 1 mg, with no effect on cortisol or aldosterone [19].

The early human trials were funded and run by the manufacturer. Two small, double-blind, placebo-controlled studies in healthy postmenopausal volunteers showed that 1 mg daily drove estradiol below the limit of detection in most women, with a half-life of about 50 hours that supported once-daily dosing [19]. Those trials were short, 10 to 14 days, and measured only hormone levels, not clinical outcomes. The evidence that anastrozole actually prevents breast cancer recurrence came later, from the massive ATAC trial (9,366 women) funded by AstraZeneca, which showed a hazard ratio for disease-free survival of 0.87 compared to tamoxifen [5, 8]. The IBIS-II prevention trial in high-risk women found a 58% reduction in invasive ER-positive breast cancers over about 5 years [10].

The mechanism is well understood at the molecular level. Anastrozole's triazole ring coordinates to the heme iron of aromatase, blocking the binding of androstenedione and testosterone [14]. The drug is selective because the active site of CYP19 is structurally distinct from other P450 enzymes, and the triazole fits it without the off-target effects of earlier inhibitors. The suppression of estrogen is near-complete in postmenopausal women, whose estrogen comes almost entirely from peripheral aromatization rather than ovarian production.

My call: anastrozole was rationally discovered through targeted medicinal chemistry against a well-characterized enzyme, and the evidence for its mechanism and estrogen-suppressing effect is strong. The confidence is high for the discovery story and the pharmacology. The confidence is moderate for the long-term net benefit in prevention, because the manufacturer-funded trials use surrogate endpoints and the fracture risk from estrogen suppression is real [5, 6].